Clinical Trial: Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

Brief Summary: Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.

Detailed Summary: Methylphenidate (MPH) is the most prescribed psychostimulant for children and adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Meta-analyses and systematic reviews have shown that MPH is safe and efficacious in attenuating the core symptoms of ADHD, promoting overall clinical improvement. However, many patients still do not show an appropriate clinical response to the MPH treatment and there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. Therefore, it is essential to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
Sponsor: Hospital de Clinicas de Porto Alegre

Current Primary Outcome: Self-reported changes in severity of ADHD symptoms [ Time Frame: 1yr ]

Evaluated by Swanson, Nolan and Pelham Rating Scale - Version IV (SNAP-IV) adapted to adults.

Assessment points at baseline, 6 weeks, 3 months, 6 months and 1 year of treatment



Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Self-reported changes in severity of oppositional defiant disorder symptoms [ Time Frame: 1yr ]

    Evaluated by Swanson, Nolan and Pelham Rating Scale - Version IV (SNAP-IV) adapted to adults.

    Assessment points at baseline, 6 weeks, 3 months, 6 months and 1 year of treatment

  • Psychiatrist's judgment of improvement of patient's symptoms [ Time Frame: 1yr ]
    Evaluated by Clinical Global Impression - Improvement scale (CGI-I). Assessment points at baseline, 6 weeks, 3 months, 6 months and 1 year of treatment


Original Secondary Outcome: Same as current

Information By: Hospital de Clinicas de Porto Alegre

Dates:
Date Received: October 31, 2016
Date Started: February 2002
Date Completion: December 2032
Last Updated: October 31, 2016
Last Verified: October 2016